HAE:NYSEHaemonetics Corporation Analysis
Data as of 2026-09-23 - not real-time
$108.42
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
At $108.42, Haemonetics Corporation shows a bullish moving-average alignment, with shorter averages sitting above longer ones. Over a rolling month the price has gained 25.2%. RSI sits at 71.0, which reads as overbought, and MACD momentum is bearish. Watch $100.53 as support and $110.45 as the nearer resistance level.
On valuation the read is overvalued — earnings multiple of 52.4 versus a 30.1 sector average, above the peer group. Revenue is growing at 5.6% on a 7.1% profit margin.
Risk scores 6 out of 10, which is elevated for this asset class. With 30-day volatility of 48.3%, a beta of 0.10 and a maximum drawdown of 40.1%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to hold, carrying 2/10 conviction.
On valuation the read is overvalued — earnings multiple of 52.4 versus a 30.1 sector average, above the peer group. Revenue is growing at 5.6% on a 7.1% profit margin.
Risk scores 6 out of 10, which is elevated for this asset class. With 30-day volatility of 48.3%, a beta of 0.10 and a maximum drawdown of 40.1%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to hold, carrying 2/10 conviction.
Top Market Events
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the medical devices & supplies - specialty...Earnings results often indicate what direction a company will take in the months ahead.Blood products company Haemonetics NYSE:HAE reported Q2 CY2026 results , with sales up 5.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- RSI at 71.0 signals overbought conditions
- Trading above the 200-day average of 74.15
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- RSI at 71.0 signals overbought conditions
- P/E of 52.4 versus sector average of 30.1
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- P/E of 52.4 versus sector average of 30.1
- 30-day volatility of 48.3%
- Price-to-book of 5.89
Key Metrics & Analysis
Financial Health
Revenue Growth5.60%
Profit Margin7.12%
P/E Ratio52.4
ROE11.20%
ROA6.60%
Debt/Equity140.26
P/B Ratio5.9
Op. Cash Flow$328.1M
Free Cash Flow$312.8M
Industry P/E30.1
Technical Analysis
TrendBullish
RSI71.0
Support$100.53
Resistance$110.45
MA 20$104.96
MA 50$94.38
MA 200$74.15
MACDBearish
VolumeStable
Fear & Greed Index94.04
Valuation
Fair Value$86.80
Target Price$111.50
Upside/Downside2.84%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.10
Volatility48.26%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.